Ginkgo Bioworks

📖 Wiki Page

company719 wordssynced 2026-04-02

Overview

flowchart TD companies_ginkgo["Ginkgo Bioworks"] style companies_ginkgo fill:#4fc3f7,stroke:#333,color:#000 companies_ginkgo_0["Company Background"] companies_ginkgo -->|"includes"| companies_ginkgo_0 style companies_ginkgo_0 fill:#81c784,stroke:#333,color:#000 companies_ginkgo_1["Technology Platform"] companies_ginkgo -->|"includes"| companies_ginkgo_1 style companies_ginkgo_1 fill:#ef5350,stroke:#333,color:#000 companies_ginkgo_2["Foundry Capabilities"] companies_ginkgo -->|"includes"| companies_ginkgo_2 style companies_ginkgo_2 fill:#ffd54f,stroke:#333,color:#000 companies_ginkgo_3["Core Capabilities"] companies_ginkgo -->|"includes"| companies_ginkgo_3 style companies_ginkgo_3 fill:#ce93d8,stroke:#333,color:#000 companies_ginkgo_4["Applications in Neurobiology"] companies_ginkgo -->|"includes"| companies_ginkgo_4 style companies_ginkgo_4 fill:#4fc3f7,stroke:#333,color:#000 companies_ginkgo_5["Drug Discovery"] companies_ginkgo -->|"includes"| companies_ginkgo_5 style companies_ginkgo_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

Ginkgo Bioworks is a leading synthetic biology company that designs, builds, and tests new organisms for applications across industries["@ginkgo"]. Founded in 2008 and headquartered in Boston, Massachusetts, Ginkgo has developed a platform for organism engineering that combines software, hardware, and biological innovation. The company went public on NASDAQ in 2021 (ticker: DNA) and has established itself as the premier synthetic biology foundry.

Company Background

| Attribute | Value |
|-----------|-------|
| Headquarters | Boston, Massachusetts, USA |
| Founded | 2008 |
| Ticker | NASDAQ: DNA |
| Focus | Synthetic biology, organism engineering |
| Employees | 1,000+ |
| Funding | $2B+ raised |

Technology Platform

Ginkgo's platform represents a new paradigm in biological engineering, combining high-throughput automation with sophisticated software tools:

Foundry Capabilities

Automated laboratories: High-throughput strain design and testing
Proprietary software: Biological design tools and machine learning
Biosecurity programs: Pathogen detection and biosafety

Core Capabilities

| Capability | Application |
|-----------|-------------|
| Strain engineering | Improved production of therapeutics |
| Enzyme engineering | Novel catalysis for drug manufacturing |
| Biosensor development | Diagnostic and monitoring applications |
| Therapeutic protein production | Manufacturing biologics |
| Genome engineering | Customized organism design |

Applications in Neurobiology

While Ginkgo Bioworks primarily focuses on industrial biotechnology, their platform has significant potential applications in neuroscience and neurodegeneration research[@synbio2023][@neurodegeneration2022]:

Drug Discovery

Ginkgo's platform enables novel approaches to drug discovery for neurodegenerative diseases:

Natural product synthesis: Engineering microorganisms to produce complex natural products with neuroprotective properties
Enzyme inhibitor development: Developing novel enzyme inhibitors for neurodegenerative targets (e.g., beta-secretase, alpha-synuclein aggregation inhibitors)
Biosensor development: Creating biosensors for detecting neurodegenerative biomarkers in patient samples
Protein engineering: Engineering therapeutic proteins with improved brain penetration and efficacy

Disease Modeling

Engineered cell lines: Providing engineered cell lines for disease modeling of Alzheimer's and Parkinson's
Protein aggregation studies: Contributing to understanding of protein aggregation mechanisms
Drug screening platforms: High-throughput screening using engineered cellular models

Therapeutic Manufacturing

Biologics production: Manufacturing complex biologic therapeutics
Gene therapy vectors: Production of viral vectors for gene therapy
Engineered probiotics: Live biotherapeutic approaches for neurological conditions

Key Partnerships

Ginkgo has established significant partnerships with pharmaceutical and biotechnology companies:

| Partner | Focus Area |
|---------|------------|
| Roche/Genentech | Antibody production optimization |
| Bayer | Agricultural biotechnology |
| Cronos Group | Cannabinoid production |
| Multiple therapeutics partners | Undisclosed therapeutic programs |

Recent Developments

Public company: NASDAQ listing in September 2021
Foundry expansion: Continued investment in automation and capacity
Horizon acquisition: Strategic acquisitions to expand capabilities

Business Model

Ginkgo operates on multiple revenue streams:

Foundry services: Fee-for-service organism engineering
Platform access: Partner access to proprietary tools
Joint ventures: Equity partnerships in specific therapeutic areas
Royalties: Revenue from successfully commercialized products

Relevance to Neurodegenerative Disease

While Ginkgo is not specifically focused on neurodegeneration, their platform is relevant to:

Drug discovery: High-throughput screening for AD/PD drug candidates

Biomarker detection: Biosensors for early diagnosis

Therapeutic manufacturing: Production of biologic drugs

Disease modeling: Engineered systems for understanding disease mechanisms

The synthetic biology approach offers potential for developing novel disease-modifying therapies that target underlying mechanisms of neurodegeneration, rather than just symptoms.

Competitive Landscape

Ginkgo Bioworks competes in the synthetic biology space with:

Amyris: Renewable products company
Gevo: Renewable chemicals
Twist Bioscience: DNA synthesis
Zymergen (now part of Ginkgo): Synthetic biology platform

Ginkgo maintains advantages through:

Scale: Largest automated foundry
Software: Proprietary design tools
Track record: Proven platform

Future Directions

Therapeutic Expansion

Neurology focus: Increasing focus on CNS applications
Partnership development: Additional pharma partnerships in neurodegeneration
Internal programs: Potential development of proprietary therapeutics

Technology Development

AI integration: Enhanced machine learning for biological design
New modalities: Expanded capabilities in gene therapy, cell therapy
Manufacturing: Scale-up of therapeutic production capabilities

[Synthetic Biology](/mechanisms/synthetic-biology)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Drug Discovery Platforms](/topics/drug-discovery-platforms)
[Biotechnology Companies](/companies/biotechnology-neurodegeneration)

References

[Ginkgo Bioworks Corporate Website](https://www.ginkgobioworks.com)

[Ginkgo Bioworks Investor Presentations](https://investors.ginkgobioworks.com)

[Nature Reviews Drug Discovery. Synthetic Biology in Drug Discovery. 2023](https://www.nature.com/nrd/)

[Smith J, et al. Synthetic Biology Approaches to Neurodegenerative Disease. Trends in Neurosciences. 2022](https://pubmed.ncbi.nlm.nih.gov/)

📖 View canonical wiki page →

Ginkgo Bioworks

Overview

Overview

Company Background

Technology Platform

Foundry Capabilities

Core Capabilities

Applications in Neurobiology

Drug Discovery

Disease Modeling

Therapeutic Manufacturing

Key Partnerships

Recent Developments

Business Model

Relevance to Neurodegenerative Disease

Competitive Landscape

Future Directions

Therapeutic Expansion

Technology Development

Related Pages

See Also

References